Introduction Understanding the balance between the benefits and risks of vaccination is essential to ensure informed and adequate public health decision making. Quantitative benefit–risk models (qBRm) represent useful tools to help decision makers with supporting benefit–risk assessment throughout the lifecycle of a medical product. However, few initiatives have been launched to harmonise qBRm approaches, specifically for vaccines. Objectives The aim of this paper was to identify publications about qBRm applied to vaccines through a systematic literature review, and to describe their characteristics. Methods Medline, Scopus and Institute for Scientific Information Web of Knowledge databases were searched to identify articles in English, pub...
BACKGROUND: Incremental cost-effectiveness and cost-utility analyses [health economic evaluations (H...
Robust and responsive epidemiological post-licensure vaccine safety studies are the backbone to hav...
To date, vaccination is the most cost-effective strategy to combat infectious diseases. Recently, a ...
Benefit/risk (B/R) assessment methods are increasingly being used by regulators and companies as an ...
OBJECTIVES: To describe all published articles that have conducted comparisons of model-based effect...
Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is...
BACKGROUND: Assessments of vaccine efficacy and safety capture only the minimum information needed f...
Funding Information: Funder—the Latvian Council of Science. Funding number—No. lzp-2019/1-0380, “Sel...
OBJECTIVES: During the last decade, with the arrival of new innovative vaccines, there was a huge in...
OBJECTIVES: During the last decade, with the arrival of new innovative vaccines, there was a huge in...
OBJECTIVES: During the last decade, with the arrival of new innovative vaccines, there was a huge in...
OBJECTIVES: During the last decade, with the arrival of new innovative vaccines, there was a huge in...
Funding Information: Funder—the Latvian Council of Science. Funding number—No. lzp-2019/1-0380, “Sel...
Background: Incremental cost-effectiveness and cost-utility analyses [health economic evaluations (H...
This entry contains data, code and document references that support the paper entitled as the entry....
BACKGROUND: Incremental cost-effectiveness and cost-utility analyses [health economic evaluations (H...
Robust and responsive epidemiological post-licensure vaccine safety studies are the backbone to hav...
To date, vaccination is the most cost-effective strategy to combat infectious diseases. Recently, a ...
Benefit/risk (B/R) assessment methods are increasingly being used by regulators and companies as an ...
OBJECTIVES: To describe all published articles that have conducted comparisons of model-based effect...
Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is...
BACKGROUND: Assessments of vaccine efficacy and safety capture only the minimum information needed f...
Funding Information: Funder—the Latvian Council of Science. Funding number—No. lzp-2019/1-0380, “Sel...
OBJECTIVES: During the last decade, with the arrival of new innovative vaccines, there was a huge in...
OBJECTIVES: During the last decade, with the arrival of new innovative vaccines, there was a huge in...
OBJECTIVES: During the last decade, with the arrival of new innovative vaccines, there was a huge in...
OBJECTIVES: During the last decade, with the arrival of new innovative vaccines, there was a huge in...
Funding Information: Funder—the Latvian Council of Science. Funding number—No. lzp-2019/1-0380, “Sel...
Background: Incremental cost-effectiveness and cost-utility analyses [health economic evaluations (H...
This entry contains data, code and document references that support the paper entitled as the entry....
BACKGROUND: Incremental cost-effectiveness and cost-utility analyses [health economic evaluations (H...
Robust and responsive epidemiological post-licensure vaccine safety studies are the backbone to hav...
To date, vaccination is the most cost-effective strategy to combat infectious diseases. Recently, a ...